PHRU

Pharvaris is a clinical-stage biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE) and other bradykinin-mediated diseases. The company's lead candidate, deucrictibant, is a potent and selective small-molecule B2 receptor antagonist designed to provide a more convenient oral alternative to current injectable treatments. Pharvaris is advancing deucrictibant in two distinct formulations: PHVS416 for on-demand treatment and PHVS719 for prophylactic treatment. The company aims to improve the quality of life for HAE patients by offering effective, well-tolerated oral options that reduce the burden of disease management. Pharvaris is currently conducting Phase 3 clinical trials to support global regulatory filings.